Related Experiment Video
Updated: May 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Use of antiarrhythmic drugs in elderly patients
Hon-Chi Lee1, Kristin Tl Huang, Win-Kuang Shen
1Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Insights
Aging significantly impacts cardiac electrophysiology and antiarrhythmic drug efficacy in older adults. Understanding these age-related changes is crucial for safe and effective arrhythmia management in the elderly.
Area of Science:
- Cardiology
- Gerontology
- Pharmacology
Background:
- Human aging is a global concern, increasing the incidence of health conditions and disability.
- Cardiac arrhythmias, such as atrial fibrillation and sudden cardiac death, rise sharply after age 60.
- Distinguishing physiological aging effects from pathological alterations in cardiac electrophysiology is vital.
Purpose of the Study:
- To differentiate normal age-related cardiac electrophysiological changes from pathological alterations.
- To examine how aging affects the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.
- To highlight considerations for antiarrhythmic drug use in elderly patients.
Main Methods:
- Review of age-related structural and electrophysiological changes in the heart.
- Analysis of how aging impacts the absorption, distribution, metabolism, and elimination of antiarrhythmic medications.
- Consideration of co-morbidities, polypharmacy, and drug-drug interactions in elderly patients.
Main Results:
- Age-related cardiac changes include hypertrophy, amyloidosis, valvular degeneration, conduction system fibrosis, and pacemaker cell loss.
- Electrophysiological changes involve altered ion channel expression and intracellular calcium overload, promoting arrhythmias.
- Aging modifies antiarrhythmic drug pharmacokinetics/pharmacodynamics, necessitating monitoring of liver/kidney function and potential dose adjustments.
Conclusions:
- Age-related cardiac alterations predispose individuals to arrhythmias.
- Antiarrhythmic drug efficacy and safety are influenced by aging, increasing susceptibility to side effects.
- Individualized antiarrhythmic therapy, considering patient physiology, comorbidities, and polypharmacy, is essential for the elderly.
Abstract:
Human aging is a global issue with important implications for current and future incidence and prevalence of health conditions and disability. Cardiac arrhythmias, including atrial fibrillation, sudden cardiac death, and bradycardia requiring pacemaker placement, all increase exponentially after the age of 60. It is important to distinguish between the normal, physiological consequences of aging on cardiac electrophysiology and the abnormal, pathological alterations. The age-related cardiac changes include ventricular hypertrophy, senile amyloidosis, cardiac valvular degenerative changes and annular calcification, fibrous infiltration of the conduction system, and loss of natural pacemaker cells and these changes could have a profound effect on the development of arrhythmias. The age-related cardiac electrophysiological changes include up- and down-regulation of specific ion channel expression and intracellular Ca(2+) overload which promote the development of cardiac arrhythmias. As ion channels are the substrates of antiarrhythmic drugs, it follows that the pharmacokinetics and pharmacodynamics of these drugs will also change with age. Aging alters the absorption, distribution, metabolism, and elimination of antiarrhythmic drugs, so liver and kidney function must be monitored to avoid potential adverse drug effects, and antiarrhythmic dosing may need to be adjusted for age. Elderly patients are also more susceptible to the side effects of many antiarrhythmics, including bradycardia, orthostatic hypotension, urinary retention, and falls. Moreover, the choice of antiarrhythmic drugs in the elderly patient is frequently complicated by the presence of co-morbid conditions and by polypharmacy, and the astute physician must pay careful attention to potential drug-drug interactions. Finally, it is important to remember that the use of antiarrhythmic drugs in elderly patients must be individualized and tailored to each patient's physiology, disease processes, and medication regimen.
Related Concept Videos
Drug Dosing: Geriatric Patients
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion